Accuray's Precision Treatment System Gains Approval in China, Expanding Cancer Care Options

6/12/24 7:39:51 AM ET

Medical/Dental Instruments

Health Care

Get the next $ARAY alert in real time by email

Accuray Incorporated (NASDAQ:ARAY) announced today that the registration dossier for the Accuray Precision® Treatment Planning System (TPS) has been approved by the Chinese National Medical Products Administration (NMPA). The Accuray Precision TPS is now available for use with the CNNC-Accuray joint venture Tomo® C radiation therapy system and in combination, will provide medical care teams with a new option for delivering extremely precise and accurate radiotherapy treatments, ultimately expanding access to care for more cancer patients in China.

Get the next $ARAY alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ARAY

Date	Price Target	Rating	Analyst
2/13/2024	$9.00	Buy	ROTH MKM
6/23/2022	$7.50	Buy	B. Riley Securities
12/22/2021	$7.50	Buy	Loop Capital

More analyst ratings

$ARAY
Leadership Updates

Live Leadership Updates

Accuray Appoints Michael Murphy as VP, Corporate Controller
MADISON, Wis., Oct. 21, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that Michael Murphy, CPA has joined the company as Vice President, Corporate Controller. Mr. Murphy will be responsible for leading the global accounting function including corporate tax, regulatory reporting, accounting policies, and risk management, along with associated budgetary and administrative operations. He will report to Accuray Senior Vice President & Chief Financial Officer Ali Pervaiz. The company also expects to appoint Mr. Murphy to the position of principal accounting officer following the filing of the company's quarterly report on Form 10-Q for the period ended September 30, 2024
10/21/24 4:05:00 PM ET
$ARAY
Medical/Dental Instruments
Health Care
Robert C. Kill Joins Accuray Board of Directors
SUNNYVALE, Calif., Feb. 1, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today the appointment of Robert C. Kill to the company's Board of Directors, effective as of January 30, 2023. Mr. Kill is a skilled healthcare executive with more than 30 years' experience transforming various healthcare-related companies. In his most recent executive position as CEO of Parata Systems, Mr. Kill grew company revenue over 5X during his tenure before it sold last year for more than $1.5 billion. Before Parata, Mr. Kill was affiliated with two private equity funds, Frazie
2/1/23 4:10:00 PM ET
$ARAY
Medical/Dental Instruments
Health Care
EDAP Appoints Medical Capital Equipment Finance Veteran Ken Mobeck as Chief Financial Officer of Company's U.S. Subsidiary
LYON, France, December 6, 2022 -- EDAP TMS SA (NASDAQ:EDAP) (the "Company"), the global leader in robotic energy-based therapies, announced today that the Company has hired medical capital equipment finance industry veteran Ken Mobeck as Chief Financial Officer of EDAP Technomed Inc., the Company's U.S. subsidiary. During his extensive career, Mr. Mobeck has demonstrated significant leadership expertise in driving transformational business growth while establishing a track record of creating lasting shareholder value. Marc Oczachowski, Chairman and Chief Executive Officer of EDAP TMS, stated, "I am very pleased to welcome Ken onboard our U.S. subsidiary. Ken is a great addition to Ryan Rh
12/6/22 8:00:00 AM ET
$ARAY
$EDAP
$HPQ
$INTC
Medical/Dental Instruments
Health Care
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Computer Manufacturing

$ARAY
Press Releases

Fastest customizable press release news feed in the world

Accuray Reports Fiscal 2025 First Quarter Financial Results
Strong Start to Fiscal Year, Raises 2025 Guidance MADISON, Wis., Nov. 6, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the first quarter ended September 30, 2024. "We continue to make solid progress in the execution of our strategic growth agenda and performed better than expected in the first quarter and are on track to deliver our fiscal 2025 plan. Our performance in the China region was strong and we saw significant interest in the recently introduced Accuray Tomo® C System and growth in our service business. I could not be mor
11/6/24 4:05:00 PM ET
$ARAY
Medical/Dental Instruments
Health Care
Accuray to Report First Quarter Fiscal 2025 Financial Results on November 6, 2024
MADISON, Wis., Oct. 23, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the first quarter of fiscal year 2025, ended September 30, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on November 6, 2024. The conference call dial-in numbers are (833) 316-0563 (USA) or (412) 317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-877-344-7529 (USA) or 1-412-317-0088 (interna
10/23/24 4:05:00 PM ET
$ARAY
Medical/Dental Instruments
Health Care
Accuray Appoints Michael Murphy as VP, Corporate Controller
MADISON, Wis., Oct. 21, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that Michael Murphy, CPA has joined the company as Vice President, Corporate Controller. Mr. Murphy will be responsible for leading the global accounting function including corporate tax, regulatory reporting, accounting policies, and risk management, along with associated budgetary and administrative operations. He will report to Accuray Senior Vice President & Chief Financial Officer Ali Pervaiz. The company also expects to appoint Mr. Murphy to the position of principal accounting officer following the filing of the company's quarterly report on Form 10-Q for the period ended September 30, 2024
10/21/24 4:05:00 PM ET
$ARAY
Medical/Dental Instruments
Health Care

$ARAY
Financials

Live finance-specific insights

Accuray Reports Fiscal 2025 First Quarter Financial Results
Strong Start to Fiscal Year, Raises 2025 Guidance MADISON, Wis., Nov. 6, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the first quarter ended September 30, 2024. "We continue to make solid progress in the execution of our strategic growth agenda and performed better than expected in the first quarter and are on track to deliver our fiscal 2025 plan. Our performance in the China region was strong and we saw significant interest in the recently introduced Accuray Tomo® C System and growth in our service business. I could not be mor
11/6/24 4:05:00 PM ET
$ARAY
Medical/Dental Instruments
Health Care
Accuray to Report First Quarter Fiscal 2025 Financial Results on November 6, 2024
MADISON, Wis., Oct. 23, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the first quarter of fiscal year 2025, ended September 30, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on November 6, 2024. The conference call dial-in numbers are (833) 316-0563 (USA) or (412) 317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-877-344-7529 (USA) or 1-412-317-0088 (interna
10/23/24 4:05:00 PM ET
$ARAY
Medical/Dental Instruments
Health Care
Accuray Reports Fourth Quarter and Fiscal 2024 Financial Results
14% Revenue and 8% Orders Growth in Q4; Company issues FY25 Guidance MADISON, Wis., Aug. 14, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the fourth quarter and fiscal 2024, ended June 30, 2024. Fourth Quarter Fiscal 2024 Summary Net revenue of $134.3 million, an increase of 13.5 percent from the same period in the prior fiscal year. Net revenue on a constant currency basis was $136.7 million, which represents a 15.6 percent increase versus the same period in the prior fiscal year.GAAP net income of $3.4 million, as compared to G
8/14/24 4:05:00 PM ET
$ARAY
Medical/Dental Instruments
Health Care

Accuray's Precision Treatment System Gains Approval in China, Expanding Cancer Care Options

Chat with this insight

Recent Analyst Ratings for $ARAY

$ARAY Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Scott Byron C covered exercise/tax liability with 22,642 shares, decreasing direct ownership by 16% to 119,333 units (SEC Form 4)

Director Huss Beverly A covered exercise/tax liability with 22,642 shares, decreasing direct ownership by 11% to 187,362 units (SEC Form 4)

SVP Chief Financial Officer Pervaiz Ali covered exercise/tax liability with 3,207 shares, decreasing direct ownership by 0.81% to 390,931 units (SEC Form 4)

$ARAY Market Insights

Live Market Insights

Long-term Customer Heidelberg University Hospital In Heidelberg, Germany, Has Selected Accuray's Radixact System, Equipped With ClearRT, Synchrony, And VOLO Ultra Optimizer Solutions, It Will Replace The Older Generation Accuray Tomotherapy System

Accuray Announced An Agreement With TrueNorth Medical Physics To Provide Radiation Oncology Departments With Third-party Support Designed To Enhance Their Department's Capabilities